DE60104194D1 - Kombination der progesteron und mifepristone für krebs-therapie - Google Patents

Kombination der progesteron und mifepristone für krebs-therapie

Info

Publication number
DE60104194D1
DE60104194D1 DE60104194T DE60104194T DE60104194D1 DE 60104194 D1 DE60104194 D1 DE 60104194D1 DE 60104194 T DE60104194 T DE 60104194T DE 60104194 T DE60104194 T DE 60104194T DE 60104194 D1 DE60104194 D1 DE 60104194D1
Authority
DE
Germany
Prior art keywords
mifepristone
progesterone
combination
cancer therapy
steroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60104194T
Other languages
English (en)
Other versions
DE60104194T2 (de
Inventor
Kevin Gaston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Application granted granted Critical
Publication of DE60104194D1 publication Critical patent/DE60104194D1/de
Publication of DE60104194T2 publication Critical patent/DE60104194T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60104194T 2000-05-03 2001-05-03 Kombination der progesteron und mifepristone für krebs-therapie Expired - Fee Related DE60104194T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0010683 2000-05-03
GBGB0010683.1A GB0010683D0 (en) 2000-05-03 2000-05-03 Cancer therapy
PCT/GB2001/001941 WO2001082910A2 (en) 2000-05-03 2001-05-03 Combination of progesterone and mifepristone for cancer therapy

Publications (2)

Publication Number Publication Date
DE60104194D1 true DE60104194D1 (de) 2004-08-12
DE60104194T2 DE60104194T2 (de) 2005-08-04

Family

ID=9890890

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60104194T Expired - Fee Related DE60104194T2 (de) 2000-05-03 2001-05-03 Kombination der progesteron und mifepristone für krebs-therapie

Country Status (13)

Country Link
US (1) US20040102422A1 (de)
EP (1) EP1278523B1 (de)
JP (1) JP2003531852A (de)
AT (1) ATE270554T1 (de)
AU (1) AU6042201A (de)
CA (1) CA2407134A1 (de)
CZ (1) CZ20023585A3 (de)
DE (1) DE60104194T2 (de)
GB (1) GB0010683D0 (de)
HU (1) HUP0300626A3 (de)
NO (1) NO20025157L (de)
PL (1) PL365755A1 (de)
WO (1) WO2001082910A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404548A (en) * 2002-06-25 2004-04-01 Wyeth Corp Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
JP4960972B2 (ja) 2005-12-30 2012-06-27 ベンタナ・メデイカル・システムズ・インコーポレーテツド 子宮頸部異形成および子宮頸癌におけるＮａ＋、Ｋ＋−ＡＴＰアーゼの発現
US9138440B2 (en) 2011-04-08 2015-09-22 Mayo Foundation For Medical Education And Research Methods for using mifepristone to reduce the number of CD14+/DR-monocytes
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP3275888B1 (de) 2016-07-28 2019-09-25 Council of Scientific & Industrial Research Hybrid aus progesteron und kationischem lipid als antikrebsmittel und verfahren zur synthese davon
KR102342620B1 (ko) 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
KR102657097B1 (ko) 2018-12-19 2024-04-15 코어셉트 쎄라퓨틱스 인코포레이티드 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제
KR102544591B1 (ko) * 2023-02-08 2023-07-17 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
DE4330234A1 (de) * 1993-09-02 1995-03-09 Schering Ag Verwendung von Gestagenen und kompetitiven Progesteronantagonisten zur Herstellung von Arzneimitteln für die weibliche Fertilitätskontrolle sowie Mittel enthaltend ein Gestagen und einen kompetitiven Progesteronantagonisten

Also Published As

Publication number Publication date
DE60104194T2 (de) 2005-08-04
HUP0300626A2 (hu) 2003-07-28
JP2003531852A (ja) 2003-10-28
EP1278523B1 (de) 2004-07-07
CA2407134A1 (en) 2001-11-08
HUP0300626A3 (en) 2003-12-29
PL365755A1 (en) 2005-01-10
GB0010683D0 (en) 2000-06-28
ATE270554T1 (de) 2004-07-15
EP1278523A2 (de) 2003-01-29
NO20025157D0 (no) 2002-10-25
WO2001082910A2 (en) 2001-11-08
CZ20023585A3 (cs) 2003-04-16
US20040102422A1 (en) 2004-05-27
WO2001082910A3 (en) 2002-09-06
NO20025157L (no) 2002-12-02
AU6042201A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
DE60104194D1 (de) Kombination der progesteron und mifepristone für krebs-therapie
NO954611L (no) Metoder og preparater for anvendelse i behandling av benigne gynekologiske sykdommer
BG66075B1 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
BR0011740A (pt) Administração de esteróides androgênicos não-orais a mulheres
DE69625483T2 (de) Transdermales pflaster zur verabreichung von 17-deacetyl norgestimat alleine oder in kombination mit einem östrogen
HK1092354A1 (en) Suspension of loteprednol etabonate and tobramycinfor topical ophthalmic use
ATE356635T1 (de) Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
EA200301022A1 (ru) Гормональная заместительная терапия
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
HUP0301433A2 (hu) Antiprogesztinek alkalmazása a sejtek apoptózisának indukálására szolgáló gyógyszerkészítmények előállítására
IS7204A (is) Notkun á (11ß, 17ß)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón við meðhöndlun á stórvægilegri geðlægðartruflun
BR0309621A (pt) Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti
BR9707748A (pt) Glicocorticóide para tratamento de doenças reumáticas.
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee